Overland Pharma Announces $117 Million China JV with Allogene Therapeutics
publication date: Dec 15, 2020
Overland Pharmaceuticals, a new Shanghai in-licensing company, announced its second drug partnership in two days: Overland will form a $117 million China JV with Allogene Therapeutics of South San Francisco to bring allogenic CAR-T drugs to China. The JV, Allogene Overland, will have greater China rights to four off-the-shelf CAR-T candidates targeting BCMA, CD70, FLT3 and DLL3. Yesterday, Overland announced a $50 million JV with Switzerland's ADC Therapeutics to develop four antibody drug conjugate drugs in China. More details....
Stock Symbol: (NSDQ: ALLO)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.